About
Orthocell is a regenerative medicine company focused on regenerating mobility for patients. They develop products for the repair of a variety of bone, nerve and tendon injuries. Orthocell’s portfolio of products include CelGro™ platform of collagen medical devices which facilitate tissue reconstruction and healing in a variety of dental and orthopaedic reconstructive applications. Striate+™ was the first product approved for guided bone and tissue regeneration in dental applications, is cleared for use in US FDA (510k), Australia (ARTG) and Europe (CE Mark) and is distributed globally by BioHorizons Implant Systems Inc. Remplir™, for peripheral nerve reconstruction, recently received approval and reimbursement in Australia and is distributed exclusively by Device Technologies in the Australian market.
Orthocell Ltd is at a commercial stage with best-in-class products generating revenue in international markets. The company has completed a scale up of its manufacturing facility and is in a strong financial position funded beyond a key upcoming catalyst - US approval of Remplir, our breakthrough nerve repair device expected in Q1 CY25.
Find more information on Orthocell's website.
